GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BeiGene Ltd.
BeiGene is a global biotechnology company focused on developing innovative cancer treatments. Its share price reflects the success of its commercial products and extensive development pipeline, making it a leader in oncology.
Share prices of companies in the market segment - Cancer cure
BeiGene is a global biotech company focused on developing and commercializing innovative cancer treatments. We've categorized it as a Cancer Treatment company. The chart below shows how investors value large oncology companies with a global presence.
Broad Market Index - GURU.Markets
BeiGene is a global biotech company that develops and commercializes innovative cancer treatments. As a component of the GURU.Markets index, it is a leader in oncology. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BGNE - Daily change in the company's share price BeiGene Ltd.
The daily price change of BeiGene, Ltd., a global oncology company, reflects the high volatility inherent in biotech. It reflects investor reactions to news about its drug sales and the results of new clinical trials.
Daily change in the price of a set of shares in a market segment - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. Oncology is one of the most volatile biotech sectors, driven by clinical trial results. The chart below reflects these fluctuations, serving as a barometer for BGNE stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
BeiGene is a global biotechnology company, a leader in the development of innovative cancer treatments. Its shares reflect its success in drug research and commercialization worldwide, making a significant contribution to the dynamism of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BeiGene Ltd.
For BeiGene, Ltd., a global biotech company, the year-over-year performance is a story about the commercialization of its oncology drugs. Its market cap growth over the past 12 months reflects the increased global sales of its blockbuster drug, Brukins. Its valuation is a bet on its potential to become a leading global player in oncology.
Annual dynamics of market capitalization of the market segment - Cancer cure
BeiGene, Ltd. is a global biotechnology company focused on developing innovative cancer drugs. Its strategy includes both in-house research and partnerships to bring its products to the global market. This chart shows how its scientific potential and commercialization success compare to the broader biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BeiGene, a global biotech company focused on oncology, is a leader in the development of new anti-cancer drugs. Its year-over-year market capitalization reflects the successful sales of its approved drugs and the expectations for its extensive pipeline of new developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BeiGene Ltd.
BeiGene is a global oncology company. Its monthly performance reflects both the growth of its commercial drugs worldwide and progress in its extensive clinical pipeline. Quarterly revenue reports and trial data are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer cure
BeiGene is a global biotech company focused on developing innovative cancer drugs. It is one of the leading oncology companies to emerge from China. The chart below shows how investors assessed the prospects of global oncology players and their ability to compete in the global pharmaceutical market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BeiGene is a global biotech company focused on oncology. Its stock price reflects both the sales success of its approved drugs and the potential of its extensive development pipeline. It is a leading company in its field, driven by scientific and commercial success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BeiGene Ltd.
BeiGene, a global biotech focused on oncology, shares reflect its commercial and scientific success. Weekly price movements depend on global sales data and the results of new clinical trials. The chart below shows how short-term events influence the valuation of this major oncology player.
Weekly dynamics of market capitalization of the market segment - Cancer cure
BeiGene is a global biotech company focused on developing innovative cancer treatments. Its extensive pipeline and presence in China create a unique profile. This chart shows how news about different drugs impacts its performance.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BeiGene is a global biotech company. This chart compares its weekly performance to the broader market. It helps understand what's driving the stock: general biotech sentiment, news from China, or the release of clinical trial data.
Market capitalization of the company, segment and market as a whole
BGNE - Market capitalization of the company BeiGene Ltd.
BeiGene, Ltd.'s market capitalization is the valuation of one of the world's leading oncology-focused biotech companies. Its valuation reflects the success of its proprietary drugs, such as Brukinsa, and its ability to compete in the global pharmaceutical market, despite being based in China.
BGNE - Share of the company's market capitalization BeiGene Ltd. within the market segment - Cancer cure
BeiGene's market share in oncology reflects its status as a global biotech company originating from China. Its enormous market weight is a reflection of its portfolio of approved drugs and extensive pipeline, making it one of the most successful and influential players in global oncology.
Market capitalization of the market segment - Cancer cure
Take a look at the chart: it's the combined market capitalization of global biotech companies focused on oncology. BeiGene, with its strong position in China and global ambitions, is one of the emerging giants. The chart's dynamics reflect its rapid growth and successful launch of new drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's the market value of one of the most prominent players in Chinese biotechnology. BeiGene, Ltd.'s market capitalization reflects its global ambitions and portfolio of innovative cancer drugs. Its economic weight reflects the growing strength of Asian science in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
BGNE - Book value capitalization of the company BeiGene Ltd.
The graph below shows BeiGene's scientific and commercial foundation. Its line reflects the value of the intellectual property for its portfolio of innovative oncology drugs, as well as its global manufacturing and commercial capabilities. Growth on the graph signifies the company's transformation into a global biopharmaceutical leader.
BGNE - Share of the company's book capitalization BeiGene Ltd. within the market segment - Cancer cure
BeiGene's resources include its modern manufacturing facilities in the US and China for the production of innovative oncology drugs, as well as global R&D centers. The chart shows the company's share of this international scientific and manufacturing infrastructure.
Market segment balance sheet capitalization - Cancer cure
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. BeiGene, a global oncology company, is one such builder. It invests in R&D centers and manufacturing facilities around the world, making it capital-intensive.
Book value of all companies included in the broad market index - GURU.Markets
BeiGene is a global biotech company specializing in the development of innovative cancer drugs. Its assets include major research centers and manufacturing facilities in the United States and China. The chart illustrates the colossal financial weight behind this "bridge" between East and West in oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BeiGene Ltd.
BeiGene is a global biotech company developing and marketing innovative cancer treatments. It already has successful drugs on the market. This chart shows how the market views its product portfolio and extensive clinical trial program. This chart evaluates both current and future cash flows.
Market to book capitalization ratio in a market segment - Cancer cure
BeiGene, Ltd. is a global biotechnology company focused on developing innovative cancer treatments. Its value lies in its robust pipeline. This chart shows how the market valuation, reflecting the potential of its pipeline, is a multiple of its book value.
Market to book capitalization ratio for the market as a whole
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. This chart shows how the market values their strong pipeline of approved drugs and extensive development pipeline. It's an example of the valuation of a major oncology player.
Debts of the company, segment and market as a whole
BGNE - Company debts BeiGene Ltd.
BeiGene, a global biotech focused on oncology, is using significant capital to fund its large-scale clinical trials and commercial expansion. This chart shows how the company is investing billions of dollars in R&D and building a global sales team to compete with major pharma giants.
Market segment debts - Cancer cure
BeiGene is a global biotech company focused on developing and commercializing innovative oncology drugs. This chart shows how its high debt load reflects its massive investments in an extensive global clinical trials program and in building an in-house sales team to compete with pharmaceutical giants.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BeiGene Ltd.
Bright Green aims to become a major producer of cannabis for research and pharmaceutical purposes in the United States. Obtaining licenses and building production facilities is a capital-intensive process. The chart shows how the company is funding its entry into this highly regulated market.
Market segment debt to market segment book capitalization - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. This chart compares its debt to the total market capitalization of the entire oncology sector. It shows how the company is funding its extensive clinical trials worldwide and building its commercial infrastructure.
Debt to book value of all companies in the market
BeiGene, Ltd. is a global biotechnology company developing and commercializing innovative cancer treatments. The company has strong positions in both China and the West. This chart of overall debt trends helps assess how BeiGene finances its extensive R&D programs and global commercial infrastructure.
P/E of the company, segment and market as a whole
P/E - BeiGene Ltd.
This chart for BeiGene, a global biotech focused on oncology, shows its valuation based on its portfolio. The P/E ratio reflects both sales of already approved drugs and investor confidence in its extensive and promising pipeline, which justifies its high valuation.
P/E of the market segment - Cancer cure
BeiGene is a global biotech company focused on developing and commercializing innovative cancer treatments. It has a strong pipeline of proprietary and licensed drugs and an extensive clinical development program. This chart shows the average valuation for the oncology sector, reflecting how investors value large and ambitious players in this field.
P/E of the market as a whole
BeiGene is a global biotech company focused on developing and commercializing innovative cancer treatments. The company has a strong presence in both China and global markets. This sentiment chart helps understand how investors value leading biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BeiGene Ltd.
BeiGene is a global biotechnology company focused on developing and commercializing innovative cancer treatments. This graph reflects future revenue expectations, which are dependent on successful sales of its key drugs and progress in clinical trials.
%20P%2FE%20BeiGene%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BeiGene-Ltd.&v=1772513887072 "Chart of the company's future (projected) P/E BeiGene Ltd.")
Future (projected) P/E of the market segment - Cancer cure
BeiGene is a global biotech company specializing in developing innovative cancer treatments. This chart compares its profitability expectations with those of other large oncology companies. It shows how investors view its strong pipeline and global reach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772513887195 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
BeiGene is a global biotech company focused on the development and commercialization of innovative oncology drugs. Its success depends on clinical trial results and drug sales. This chart, reflecting overall market optimism, influences biotech company valuations and the availability of capital for expensive R&D.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513887276 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BeiGene Ltd.
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative oncology drugs. Its financial performance is driven by sales growth of its own drugs and partnerships. This chart shows the company's journey from an R&D organization to a fully fledged commercial entity.
Profit of companies in the market segment - Cancer cure
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative oncology drugs. This chart, showing overall sector profitability, reflects the race to develop new cancer drugs. BeiGene's successful blockbusters and its extensive pipeline directly impact treatment standards and the financial performance of the entire industry.
Overall market profit
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. With a strong presence in both China and the West, the company is a leader in oncology and an example of successful globalization in biopharma.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BeiGene Ltd.
BeiGene is a global biotechnology company specializing in the development of innovative oncology drugs. Future profit projections depend on sales of its key drugs and the success of clinical trials of new candidates.
%20profit%20of%20the%20company%20BeiGene%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BeiGene-Ltd.&v=1772513887541 "Graph of future (projected) profit of the company BeiGene Ltd.")
Future (predicted) profit of companies in the market segment - Cancer cure
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative oncology therapeutics. This chart shows future revenue projections for the entire oncology sector. It allows you to assess how the company's robust pipeline and global presence compare to overall financial expectations in the field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772513887549 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
BeiGene is a global biotech company focused on developing innovative cancer treatments. Unlike early-stage companies, BeiGene already has commercial products. However, this timeline is important because it impacts the overall valuation of the biotech sector and the willingness of healthcare systems to pay for expensive oncology drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513887551 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BeiGene Ltd.
BeiGene is a global biotech company developing and commercializing innovative cancer treatments. This metric, which correlates market capitalization with rapidly growing revenue, reflects its emergence as a major player. It reflects the high premium investors are paying for its strong pipeline and extensive scientific platform.
P/S market segment - Cancer cure
BeiGene, Ltd. is a global biotechnology company focused on the development and commercialization of innovative oncology therapeutics. The company has a strong portfolio of proprietary and licensed products. This chart reflects the market's willingness to pay for revenue in the oncology sector, demonstrating confidence in BeiGene's scientific developments and commercial success.
P/S of the market as a whole
BeiGene, Ltd. is a global biotechnology company focused on the discovery, development, and commercialization of innovative oncology therapeutics. The company has a strong presence both in China and globally. This chart helps understand how the market values leading biotech companies with global reach.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BeiGene Ltd.
BeiGene is a global biotechnology company developing and commercializing innovative cancer treatments. This chart shows how investors value the company based on projected future sales of its drug portfolio. It reflects their confidence in its scientific developments and commercial success in the global market.
%20P%2FS%20BeiGene%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BeiGene-Ltd.&v=1772513887574 "The graph of the company's future (projected) P/S BeiGene Ltd.")
Future (projected) P/S of the market segment - Cancer cure
BeiGene is a global biotechnology company focused on developing and commercializing innovative oncology drugs. This chart shows the average estimated future sales in the cancer treatment sector. It helps understand how investors view BeiGene's robust pipeline, including Brukins and Tislelizumab, and its global commercial prospects.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772513887589 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
BeiGene (BGNE) is a global biotech company specializing in the development of innovative cancer treatments. Their success depends on the results of clinical trials and the global sales of their products. This chart does not reflect their potential in the fight against cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513887615 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BeiGene Ltd.
BeiGene, a global biotech company, generates revenue from sales of its innovative cancer treatments. Unlike many competitors, it has its own portfolio of commercialized products. This growth reflects increased sales of its flagship drugs in the US, Europe, and China.
Sales of companies in the market segment - Cancer cure
BeiGene is a global biotechnology company focused on developing innovative oncology therapeutics. Its revenue breakdown shows how revenue is split between sales of its proprietary drugs (such as Brukinsa) and royalties from partnerships, reflecting its successful commercialization strategy.
Overall market sales
BeiGene, Ltd. is a global biotechnology company specializing in the development of innovative oncology drugs. Its success depends on the results of clinical trials and the commercialization of its drugs worldwide. Demand for oncology drugs is inelastic, but the overall economics shown in this chart influence the solvency of healthcare systems in different countries.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BeiGene Ltd.
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative oncology drugs. This chart shows analyst expectations for sales growth and research progress for its key drugs.
%20sales%20of%20the%20company%20BeiGene%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BeiGene-Ltd.&v=1772513887736 "Schedule of future (projected) sales of the company BeiGene Ltd.")
Future (projected) sales of companies in the market segment - Cancer cure
BeiGene, Ltd. is a global biotechnology company focused on the development and commercialization of innovative oncology therapeutics. This chart shows the outlook for the cancer treatment sector. Its sustained growth reflects significant investment and scientific advances in the fight against cancer, where BeiGene is a key player.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772513887758 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Investment activity in the pharmaceutical industry, closely linked to the forecasts in this chart, determines BeiGene's prospects. The global biotech company, focused on oncology, depends on successful sales of its drugs and the ability to finance its extensive development pipeline, which is easier in a growing economy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513887789 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BeiGene Ltd.
BeiGene is a global biotechnology company developing and commercializing innovative oncology drugs. This chart shows its path to profitability. Profitability is the result of a balance between growing revenues from proprietary drugs and significant investments in global clinical research.
Market segment marginality - Cancer cure
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. Its profitability depends on the success of its extensive oncology drug portfolio in global markets, including China and the US. This chart shows the average profitability in the pharmaceutical industry, helping to assess the success of its global strategy.
Market marginality as a whole
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative oncology drugs. Its growth depends on successful sales and research results. This growth curve, reflecting the state of the economy, influences healthcare budgets worldwide, which determine the availability and pricing of new cancer drugs.
Employees in the company, segment and market as a whole
Number of employees in the company BeiGene Ltd.
BeiGene, Ltd. is a global biotechnology company focused on the development and commercialization of innovative oncology therapeutics. This chart shows a large and rapidly growing team of scientists, clinicians, and sales professionals. This growth reflects their successful transition from an R&D startup to a fully-fledged pharmaceutical company with a global presence.
Share of the company's employees BeiGene Ltd. within the market segment - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. This chart shows its share of the total number of oncology researchers. This reflects its extensive clinical programs and its transformation from a Chinese startup to a leading global player.
Number of employees in the market segment - Cancer cure
BeiGene, Ltd. is a global biotechnology company focused on the development and commercialization of innovative oncology therapeutics. This chart, showing employment in the cancer treatment sector, is key. The enormous growth in the number of scientists and clinicians in this field worldwide demonstrates unprecedented investment and scientific progress in the fight against cancer.
Number of employees in the market as a whole
BeiGene is a global biotechnology company focused on developing innovative cancer treatments. This total employment chart reflects the global economy's ability to finance healthcare. Economic growth allows healthcare systems around the world to purchase cutting-edge oncology drugs, making them accessible to millions of patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BeiGene Ltd. (BGNE)
BeiGene (BGNE) is a global biotechnology company developing and commercializing innovative cancer treatments. It is a full-cycle company, covering everything from R&D (intellectual capital) to sales. This metric reflects the company's strong R&D pipeline and growing commercial infrastructure.
%20of%20the%20company%20BeiGene%20Ltd.%20(BGNE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BeiGene-Ltd.-BGNE&v=1772513887961 "Chart of market capitalization per employee (in thousands of dollars) of the company BeiGene Ltd. (BGNE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
BeiGene is a global biotech company developing and commercializing innovative cancer treatments. It combines both R&D and sales. This metric helps assess the balance of its model and how the market perceives its ability to create value through both science and commercialization.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772513888039 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. Its market capitalization reflects the value of its extensive pipeline. This metric demonstrates its high cost per employee, as the company combines extensive clinical trials with scientific breakthroughs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513888057 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BeiGene Ltd. (BGNE)
BeiGene is a global oncology company that has achieved a rare feat: it has both its own commercial drugs (such as Brukinsa) and a massive R&D pipeline. This graph illustrates the delicate balance between the extent to which the profits generated by the commercial team from already sold drugs can offset the enormous costs (negative profits) of the thousands of scientists working on future discoveries.
%20Chart%20BeiGene%20Ltd.%20(BGNE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BeiGene-Ltd.-BGNE&v=1772513888071 "Company Profit Per Employee (in thousands of dollars) Chart BeiGene Ltd. (BGNE)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
BeiGene is a global biotech company focused on developing innovative cancer treatments. This chart reflects the effectiveness of its business model, which includes both proprietary research and product commercialization. As sales of its products grow globally, this metric should show steady growth.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772513888073 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
BeiGene (BGNE) is a global biotech company (founded in China) developing and commercializing innovative oncology drugs. It is a hybrid of R&D and commercial pharmaceuticals. This metric reflects how effectively the company balances expensive R&D with profits from the sale of its blockbuster drugs (like Brukinsa).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513888076 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BeiGene Ltd. (BGNE)
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. Unlike many biotechs, they have successful products on the market. This chart shows their high revenue per employee, reflecting their commercial success.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BeiGene-Ltd.-BGNE&v=1772513888078 "Sales chart per company employee BeiGene Ltd. (BGNE)")
Sales per employee in the market segment - Cancer cure
BeiGene is a global biotech company developing and commercializing innovative cancer treatments (such as Brukins). This is R&D and sales. This chart shows how productive their commercial team and R&D engine are. It reflects their ability to generate revenue from sales of their blockbusters.
Sales per employee for the market as a whole
Stepan Company (SCL) is a chemical company producing "specialty" and "intermediate" chemicals. Their products are used in everything from detergents and shampoos (surfactants) to polymers and fertilizers. This chart shows efficiency in chemical production. Managing chemical plants requires capital investment and expertise. An increase in this indicator indicates process automation.
Short shares by company, segment and market as a whole
Shares shorted by company BeiGene Ltd. (BGNE)
BeiGene (BGNE) is a large Chinese biotech company developing oncology drugs. This chart shows the number of short positions. Short positions may be related to geopolitical risks (US-China tensions) or massive R&D costs, which are putting pressure on profits.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BeiGene-Ltd.-BGNE&v=1772513888144 "Short Shares Chart for the Company BeiGene Ltd. (BGNE)")
Shares shorted by market segment - Cancer cure
BeiGene (BGNE) is a global biotech company focused on developing innovative cancer treatments. The chart below shows the overall short position in the oncology biotech sector. It reflects investor skepticism regarding development costs and competition.
Shares shorted by the overall market
BeiGene is a major oncology biotech with significant R&D expenditures. This chart illustrates the overall market pessimism. When investors are fearful, they sell off growth stories that require capital. Geopolitical risk (China) adds to this, exacerbating sell-offs during periods of global instability.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BeiGene Ltd. (BGNE)
BeiGene (BGNE) is a global biotech company focused on developing innovative cancer treatments. Its portfolio and development pipeline rival global leaders. This oscillator measures trend strength. It shows when the stock is overbought (above 70) on positive trial data or oversold (below 30) on competitive news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BeiGene-Ltd.-BGNE&v=1772513888166 "RSI 14 indicator chart for the company's stock BeiGene Ltd. (BGNE)")
RSI 14 Market Segment - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. They have a strong pipeline of proprietary oncology drugs (such as Brukinsa). This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For BeiGene, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BGNE (BeiGene Ltd.)
BeiGene is a global biotech company that has become a giant in oncology. They develop and commercialize innovative cancer drugs (such as Brukinsa). This chart shows the average 12-month analyst forecast, reflecting their assessment of Brukinsa's commercial success and the potential of their R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BGNE-BeiGene-Ltd.&v=1772513888172 "A chart showing analyst consensus forecasts for the expected stock price. BGNE (BeiGene Ltd.)")
The difference between the consensus estimate and the actual stock price BGNE (BeiGene Ltd.)
BeiGene (BGNE) is a global oncology titan with Chinese roots. Their blockbuster Brukins and deep R&D portfolio pose a challenge to Big Pharma. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their valuation of this powerful oncology portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BGNE-BeiGene-Ltd.&v=1772513888209 "A chart showing the difference between the consensus forecast and the actual stock price. BGNE (BeiGene Ltd.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
BeiGene (BGNE) is a global biotech company (with roots in China) that has become "Big Pharma." It develops and markets innovative cancer drugs (Brukinsa) worldwide. This chart shows general expectations for the cancer treatment sector. It reflects whether experts believe in the success of global oncology R&D platforms.
Analysts' consensus forecast for the overall market share price
BeiGene (BGNE) is a global biotech giant born in China. They have become one of the world's leading oncology companies, developing and selling blockbuster drugs (like Brukins). This chart shows the overall risk appetite. It reflects the willingness of investors to invest in fast-growing but complex global R&D companies operating at the intersection of the US and Chinese markets.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BeiGene Ltd.
BeiGene is a global biotech giant from China. Their specialty is developing (not copying) and globally commercializing blockbusters (Brukins, Tislelizumab) in oncology, which compete with (and defeat) Big Pharma. This chart is a summary indicator of their growth story. It reflects their (explosive) sales growth and (critically) their geopolitical discount (China risks).
AKIMA Market Segment Index - Cancer cure
BeiGene is a global biotech giant with Chinese roots. They develop and commercialize innovative cancer treatments worldwide, challenging big pharma. This chart compares their composite index to the sector, showing how their global oncology strategy outperforms their competitors.
The AKIM Index for the overall market
BeiGene is a global biotech company with roots in China, specializing in oncology (Brukins). This chart, showing the average (global/US) market share, serves as a benchmark. It helps assess how BGNE, an aggressive competitor to big pharma, compares to overall trends.
